D1.229 - Real-life observational study on allergen-specific Immunotherapy with double-polymerized allergoids (Modigoid Cup a1) in patients allergic to Cupressus Arizonica pollen

Modigoid Cup a1 is vaccine purified molecules and double polymerization to enhance immunogenicity, reduce allergenicity, and improve safety, supported by an aluminum-hydroxide adjuvant. Preliminary results show good tolerability, improved symptom control, and early immunomodulatory effects, including reductions in specific IgE. Clinical symptoms of Cupressus arizonica allergy mainly affect the upper airways, often causing allergic rhinitis and conjunctivitis, with possible lower airway involvement in highly sensitive or polysensitized patients.Symptom monitoring relies on validated tools such as RCAT, nasal cytology, IgE measurement, and skin prick testing. Early diagnosis and appropriate management are essential, especially in winter when symptoms may mimic respiratory infections. Allergen-specific immunotherapy with dual-polymerized molecular allergoids, such as Modigoid®, offers a promising approach by reducing allergenicity while preserving immunogenicity. Because real-world clinical evidence for cypress-specific formulations is lacking, an observational study is needed to assess their efficacy and support evidence-based therapeutic use. The observational study evaluates the efficacy and tolerability of Modigoid® Cup a1 immunotherapy in patients allergic to Cupressus arizonica pollen. The formulation, highly specific for the molecular allergen Cup a1, is designed to optimize immune response and the safety for the patients. Our aim is to provide new evidence to support more effective and personalized therapeutic strategies for cypress allergy management.

The study included 21 participants (mean age 33), with most receiving Modigoid® Cup a1 and showing varied sensitization profiles. Over roughly 8–10 months of therapy, dosing was consistent, with an average cumulative dose of 59.3 µg per patient. Across 108 administrations, only two mild Grade 1 reactions occurred, confirming a highly safety and tolerability profile.

The patients underwent skin prick testing, nasal cytology, RCAT diary completion, and IgE measurement.An overall improvement in symptoms was observed starting from the first year.These findings suggest an early and clinically meaningful response to the immunotherapy protocol.

The Modigoid Cup a1 vaccine features a highly specific molecular design based on purified molecules and double polymerization, which enhances immunogenicity while reducing allergenicity.Polymerization decreases IgE-binding capacity, improving safety, and aluminum hydroxide is used as an adjuvant to strengthen adaptive immune activation.Preliminary findings indicate good clinical efficacy and tolerability in patients with cypress allergy.Notably, improvements in symptom control and early signs of immunomodulation, including reduced specific IgE levels, were observed.